Histone Deacetylase Inhibitors Market Report 2026

Histone Deacetylase Inhibitors Market Overview

• Histone Deacetylase Inhibitors market size has reached to $1.29 billion in 2025 • Expected to grow to $1.81 billion in 2030 at a compound annual growth rate (CAGR) of 6.8% • Growth Driver: The Rising Incidence Of Cancer With Implications And Strategies For The Future • Market Trend: Product Innovation In Histone Deacetylase Inhibitors With Advancing Therapeutic Possibilities • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Histone Deacetylase Inhibitors Market?

Histone deacetylase inhibitors are a class of compounds that interfere with the function of histone deacetylases, enzymes involved in removing acetyl groups from histone proteins. This inhibition can result in increased acetylation of histones, leading to relaxed chromatin structure and altered gene expression. The main classification types of histone deacetylase inhibitors are Class I Histone deacetylases (HDACs), Class II Histone deacetylases (HDACs), Class III Histone deacetylases (HDACs), and others. Histone deacetylases (HDACs) refer to a group of enzymes that remove acetyl groups from histone proteins, leading to chromatin condensation and transcriptional repression. which can be administered via oral, injectable, and distributed through hospital pharmacies, online pharmacies, retail pharmacies, and others. It can be useful for various applications, including oncology, neurology, and others, and its end users are hospitals, home care, specialty clinics, and others.

What Is The Histone Deacetylase Inhibitors Market Growth Forecast?

The histone deacetylase inhibitors market size is expected to see strong growth in the next few years. It will grow to $1.81 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to rising global cancer incidence, growing pipeline of epigenetic-based therapies, increasing focus on precision oncology approaches, expansion of clinical trials for neurological and inflammatory indications, demand for more selective and safer epigenetic drugs. Major trends in the forecast period include increasing use of hdac inhibitors in oncology treatment regimens, growing focus on selective and isoform-specific hdac inhibitors, rising adoption of combination therapies involving hdac inhibitors, expansion of hdac inhibitor research beyond cancer indications, steady growth in oral hdac inhibitor formulations.

Global Histone Deacetylase Inhibitors Market Segmentation

1) By Classification: Class I Histone Deacetylases (HDACs), Class II Histone Deacetylases (HDACs), Class III Histone Deacetylases (HDACs), Other Classifications 2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration 3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels 4) By Application: Oncology, Neurology, Other Applications 5) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users Subsegments: 1) By Class I Histone Deacetylases (HDACs): HDAC1 Inhibitors, HDAC2 Inhibitors, HDAC3 Inhibitors, HDAC8 Inhibitors 2) By Class II Histone Deacetylases (HDACs): HDAC4 Inhibitors, HDAC5 Inhibitors, HDAC6 Inhibitors, HDAC7 Inhibitors, HDAC9 Inhibitors, HDAC10 Inhibitors 3) By Class III Histone Deacetylases (HDACs): Sirtuin 1 (SIRT1) Inhibitors, Sirtuin 2 (SIRT2) Inhibitors, Sirtuin 3 (SIRT3) Inhibitors, Sirtuin 4 (SIRT4) Inhibitors, Sirtuin 5 (SIRT5) Inhibitors, Sirtuin 6 (SIRT6) Inhibitors, Sirtuin 7 (SIRT7) Inhibitors 4) By Other Classifications: Dual-acting HDAC Inhibitors, Pan-HDAC Inhibitors, Selective HDAC Inhibitors, Combination Inhibitors (HDAC + Other Mechanisms)

What Is The Driver Of The Histone Deacetylase Inhibitors Market?

The increasing incidence of cancer is expected to propel the growth of the histone deacetylase inhibitors market going forward. The rising incidence of cancer is primarily attributed to aging populations, increased exposure to risk factors such as tobacco, diet, and environmental pollutants, and improved diagnostic techniques leading to earlier and more frequent detection. Histone deacetylase inhibitors treat cancer by altering chromatin structure, leading to the activation of tumor suppressor genes and suppression of oncogenes, thereby inducing cell cycle arrest and apoptosis in cancer cells. For instance, in February 2024, according to the World Health Organization, a US-based intergovernmental organization, approximately 35 million new cancer cases were predicted in 2050, a 77% increase from the estimated 20 million cases in 2022. Therefore, the increasing incidence of cancer is driving the growth of the histone deacetylase inhibitors industry.

Key Players In The Global Histone Deacetylase Inhibitors Market

Major companies operating in the histone deacetylase inhibitors market are Syndax Pharmaceuticals Inc., MEI Pharma Inc., Italfarmaco S.p.A., Shenzhen Chipscreen Biosciences Co. Ltd., Celgene Corporation, Spectrum Pharmaceuticals Inc., Curis Inc., Onxeo SA, Celleron Therapeutics, Forum Pharmaceuticals Inc., Merck & Co. Inc., AstraZeneca plc, Novartis AG, Eisai Co. Ltd., Karyopharm Therapeutics Inc., Medivir AB, Huya Bioscience International LLC, Crystal Genomics Inc., Midatech Pharma PLC, Regenacy Pharmaceuticals Inc.

Global Histone Deacetylase Inhibitors Market Trends and Insights

Major companies operating in the histone deacetylase inhibitors market are focusing on developing innovative product formulations, such as oral histone deacetylase (HDAC) inhibitors, to expand treatment options and improve patient convenience and compliance. An oral histone deacetylase (HDAC) inhibitor is a drug taken by mouth that targets HDAC enzymes involved in gene regulation and is potentially used in treating various diseases, including cancer and inflammatory conditions. For instance, in March 2024, Italfarmaco S.p.A., an Italy-based pharmaceutical company, received Food and Drug Administration approval for Duvyzat (givinostat), an oral histone deacetylase (HDAC) inhibitor, for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 6 years and older. Duvyzat is a histone deacetylase (HDAC) inhibitor that mitigates the sequence of events leading to muscle damage, potentially slowing the progression of muscle deterioration associated with DMD. By inhibiting HDAC overactivity, it reduces inflammation and fibrosis while promoting muscle fiber regeneration. The approval is based on the pivotal phase 3 EPIDYS trial, which met its primary endpoint, demonstrating that patients on Duvyzat showed a statistically significant decrease in the time to complete the four-stair climb assessment compared to placebo.

What Are Latest Mergers And Acquisitions In The Histone Deacetylase Inhibitors Market?

In January 2024, Bristol Myers Squibb, a US-based pharmaceutical industry company, acquired Mirati Therapeutics Inc. for an undisclosed amount. Through this acquisition, Bristol Myers aims to significantly strengthen and diversify its oncology portfolio, which includes the commercialized lung cancer medicine KRAZATI (adagrasib) and a leading KRAS and KRAS enabling program with two Phase 1 candidates, aiming to accelerate the development and delivery of innovative medicines and enhance BMS' long-term growth in cancer treatment. Mirati Therapeutics Inc. is a US-based targeted oncology company that focuses on the development of cancer therapeutics and offers histone deacetylase inhibitors.

Regional Insights

North America was the largest region in the histone deacetylase inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Histone Deacetylase Inhibitors Market?

The histone deacetylase inhibitors market consists of sales of bioinformatics tools, cell culture systems, laboratory equipment, and diagnostic devices. The market value includes the value of related goods sold by the service provider or included within the service offering. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Histone Deacetylase Inhibitors Market Report 2026?

The histone deacetylase inhibitors market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the histone deacetylase inhibitors industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.